type in your search and press enter
NeuroMetrix, Inc. Announces Date for First Quarter 2019 Financial Results Conference Call
You May Also Like
Origin™ Announces Positive Interim Results from Phase IIb Dose-Ranging Study for Diabetic Foot Ulcers
Interim results demonstrate strong evidence of healing and favorable safety profileHighest-performing arm (4X per ...
Intercept Announces Updated U.S. Prescribing Information for Ocaliva® (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical ...
Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer ...
